Content area

Abstract

Radioresistance remains to be a major obstacle in the management of patients with advanced prostate cancer (PCa). We have identified a mature miR-17-3p processed from the 3′ arm of precursor miR-17, which appeared to be able to inhibit three major antioxidant enzymes located in mitochondria, i.e., manganese superoxide dismutase (MnSOD), glutathione peroxidase 2 (Gpx2), and thioredoxin reductase 2 (TrxR2). Here we show that upregulation of miR-17-3p remarkably sensitized PCa cells to ionizing radiation (IR). Reductions of the three antioxidants led to increasing cellular reactive oxygen species (ROS) accumulation as well as declining mitochondrial respiration. The miR-17-3p-mediated dysfunction of mitochondrial antioxidants apparently sensitizing IR therapy was manifested in vitro and in vivo. Substantially, the miR-17-3p effect on suppression of the antioxidants can be efficiently eliminated or attenuated by transfecting with either an miR-17-3p inhibitor or each of the related antioxidant cDNA expression constructs. Overall, in addition to the insights into the functional assessments for the duplex of miR-17-5p and miR-17-3p, the present study highlights the rigorous evidence that demonstrated suppression of multiple mitochondrial antioxidants by a single microRNA (miRNA), thereby providing a promising approach to improve radiotherapy for advanced PCa by targeting mitochondrial function.

Details

Title
miR-17-3p Downregulates Mitochondrial Antioxidant Enzymes and Enhances the Radiosensitivity of Prostate Cancer Cells
Author
Xu, Zhi 1 ; Zhang, Yanyan 2 ; Ding, Jiaji 2 ; Hu, Weizi 2 ; Tan, Chunli 2 ; Wang, Mei 3 ; Tang, Jinhai 4 ; Xu, Yong 5 

 The Forth Clinical School of Nanjing Medical University, 140 Hanzhong Road, Nanjing 210029, China; Jiangsu Cancer Hospital & Jiangsu Institute of Cancer Research & Nanjing Medical University Affiliated Cancer Hospital, 42 Baiziting, Nanjing 210009, China 
 Jiangsu Cancer Hospital & Jiangsu Institute of Cancer Research & Nanjing Medical University Affiliated Cancer Hospital, 42 Baiziting, Nanjing 210009, China 
 Department of General Surgery, First Affiliated Hospital with Nanjing Medical University, 300 Guangzhou Road, Nanjing 210029, China 
 The Forth Clinical School of Nanjing Medical University, 140 Hanzhong Road, Nanjing 210029, China; Department of General Surgery, First Affiliated Hospital with Nanjing Medical University, 300 Guangzhou Road, Nanjing 210029, China 
 The Forth Clinical School of Nanjing Medical University, 140 Hanzhong Road, Nanjing 210029, China; Jiangsu Cancer Hospital & Jiangsu Institute of Cancer Research & Nanjing Medical University Affiliated Cancer Hospital, 42 Baiziting, Nanjing 210009, China; Jiangsu Key Lab of Cancer Biomarkers, Prevention and Treatment, Nanjing Medical University, 101 Longmian Avenue, Nanjing 211166, China 
Pages
64-77
Section
Original Article
Publication year
2018
Publication date
Dec 7, 2018
Publisher
Elsevier Limited
e-ISSN
21622531
Source type
Scholarly Journal
Language of publication
English
ProQuest document ID
2308419925
Copyright
©2018. The Author(s)